Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at panobinostat for advanced cancer to see how your kidneys affect what happens to the drug in your body
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial aimed find out more about how the body absorbs and gets rid of a drug called panobinostat. It was for people with a solid tumour that had spread (advanced cancer). A
More about this trial
One of the important jobs that your kidneys do is to get rid of drugs from the body. But if you have
Panobinostat is a drug that blocks certain proteins (
Studying what happens to a drug in the body is called
The aims of this trial were to
- Find out more about what happens to panobinostat in people with different levels of kidney function
- Learn more about the side effects
Summary of results
The study team found that it was safe to give panobinostat to people with kidney problems and the side effects were mild.
37 people took part in this study. Of those, 26 had kidney problems that ranged from mild to severe.
The researchers took blood samples from everyone before the first dose of panobinostat then every few hours after having the drug and a final sample after 96 hours. They collected regular urine samples up to 24 hours after the 1st dose. They also took more blood samples from the people who continued having panobinostat to check the levels of the drug in their blood.
The researchers looked at the blood and urine samples. They found that the level of panobinostat in the body wasn’t higher in the people who had kidney problems and wasn’t any higher in the people with severe kidney problems.
The main side effects of panobinostat were
- Feeling or being sick
- Tiredness (fatigue)
- Loss of appetite
- Bleeding problems
- Breathing problems
These didn’t seem to be much worse in people who had kidney problems.
The trial team concluded that it is safe to give panobinostat to people with mild to severe kidney problems without having to change the starting dose of the drug for this group of people.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Syed Hussain